Bayer’s Pharmaceutical Advances Struggle to Offset the Glyphosate Sword of Damocles
Veröffentlicht: 04.06.2026 um 14:43 Uhr, Redaktion boerse-global.de
The stark divide between Bayer’s operational progress and the market’s deep-seated skepticism has rarely been this wide. While the company secures accelerated FDA reviews for three key drug candidates and installs a new chief financial officer, its stock remains pinned down by the unresolved Roundup litigation — a legal overhang so severe that Chief Executive Bill Anderson has warned it could halt all US production of glyphosate.
Shares closed Wednesday at €34.52 and have since edged up 2.46% to €35.37, but that modest bounce does little to reverse a year-to-date decline of 6.98%. The stock now sits 29.16% below its 52-week high, though it is only 1.10% under its 200-day moving average. Over the past twelve months, Bayer has gained 40.08%, a figure that masks the erosion of recent months.
A Regulatory Nod That Went Largely Unnoticed
Beneath the surface of the legal drama, the pharmaceuticals division is quietly delivering. The US Food and Drug Administration has granted expedited review status to three of Bayer’s investigational drugs: the anticoagulant Asundexian, the kidney treatment Kerendia, and Sevabertinib for a specific form of lung cancer. While accelerated status does not guarantee commercial success, it signals the agency’s recognition of unmet medical need and validates Bayer’s ability to advance its pipeline.
The company is also strengthening its ophthalmology franchise through the planned acquisition of Perfuse Therapeutics, a move that homes in on existing core competencies rather than scattering resources across unrelated fields. That strategic discipline fits the narrative new CFO Judith Hartmann is expected to enforce since taking the helm of the finance division on June 1, 2026. With a market capitalisation of roughly €34.5 billion, the margin for error remains thin, and Hartmann’s task is to enforce capital discipline while managing a balance sheet still scarred by litigation costs.
Should investors sell immediately? Or is it worth buying Bayer?
The Glyphosate Ultimatum
Investor mistrust, however, is not directed at the pipeline. It is trained on the estimated 40,000 outstanding Roundup lawsuits. Anderson has reiterated that Bayer has no plans to spin off Monsanto, but he drew a hard line: without a legal resolution, there will be no glyphosate produced in the United States. Bayer is the sole domestic manufacturer of the active ingredient, making that warning both a political pressure point and a stark operational contingency.
This stance leaves the company in a strategic straitjacket. Anderson has previously said structural changes remain on the table but not for now; the priority is to deliver operational results first and tackle structure later. Investors, however, see 2026 as a make-or-break year. They want tangible progress on the legal front alongside the financial results that will determine whether the current strategy holds or a more radical restructuring becomes unavoidable.
Technicals Tell a Tale of Two Timelines
On a short-term basis, the stock has broken below its 50-day moving average of €38.50, and the relative strength index at 33.0 points to oversold conditions — a classic setup for a potential snapback, though hardly a guarantee. The support zone around €34 has so far held, providing a tentative floor for those willing to bet on a reversal.
Bayer at a turning point? This analysis reveals what investors need to know now.
Operationally, the first quarter delivered solid across-the-board business performance, with Crop Science leading the annual start. The currency-adjusted full-year forecast for 2026 has been confirmed, and management points to a leaner, faster organisation. Yet every positive data point gets discounted by the Roundup overhang. The stock is no longer a distressed case, but it is not yet a convincing turnaround either.
Bayer’s near-term fate will likely be determined by two factors: whether the company can convert regulatory momentum into commercial traction, and whether it can achieve concrete legal progress on glyphosate. Until both fronts move in tandem, the structural debate will remain a permanent fixture of the investment case.
Ad
Bayer Stock: New Analysis - 4 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
